Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 5,574 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 5,574 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $304,228.92. Following the transaction, the chief executive officer now owns 154,828 shares of the company’s stock, valued at approximately $8,450,512.24. This trade represents a 3.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Disc Medicine Stock Performance

Disc Medicine stock opened at $54.52 on Friday. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The firm has a market capitalization of $1.62 billion, a PE ratio of -13.70 and a beta of 0.73. The business’s 50-day simple moving average is $59.05 and its 200-day simple moving average is $55.19.

Analyst Ratings Changes

IRON has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a research report on Tuesday, November 5th. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $66.00 to $110.00 in a report on Monday, November 4th. Scotiabank upped their price objective on shares of Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Wednesday, January 22nd. Finally, Stifel Nicolaus raised their target price on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a report on Friday, January 24th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $88.90.

Institutional Trading of Disc Medicine

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Disc Medicine by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,717 shares of the company’s stock valued at $281,000 after purchasing an additional 2,813 shares during the period. Quest Partners LLC acquired a new stake in Disc Medicine in the 3rd quarter worth $131,000. Intech Investment Management LLC bought a new position in shares of Disc Medicine during the 3rd quarter worth about $228,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Disc Medicine by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 160,554 shares of the company’s stock valued at $7,890,000 after buying an additional 19,401 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.